Additionally, psoriatic inflammation induced by IL-17 is limited by reactive oxygen species in mice in vivo [66], and no change in ROS production was observed in IL-17 inhibitor, secukinumab-treated psoriatic arthritis patients, despite the positive response to therapy and resolution of symptoms [67]. This evidence concerns the gene IL17A and psoriatic arthritis.